Clinical analysis of the effect of fludarabine combined with post-transplantation cyclophosphamide in haploid hematopoietic stem cell transplantation
10.12092/j.issn.1009-2501.2022.03.008
- Author:
Tiantian WANG
1
;
Junjie CAO
1
;
Xuhui LIU
1
;
Renzhi PEI
1
;
Ying LU
1
Author Information
1. Department of Hematology, the Affiliated People's Hospital of Medical College of Ningbo University
- Publication Type:Journal Article
- Keywords:
Anti-thymoglobulin;
Graft-versus-host disease;
Haploidentical;
Hematopoietic stem cell transplantation;
Post-transplant cyclophosphamide
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(3):295-301
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the therapeutic method of fludarabine combined with subsequent cyclophosphamide in the prevention of GVHD in haploid hematopoietic stem cell transplantation. METHODS: A total of 52 patients receiving PTCY (50 mg/kg, on days 3 and 4) were matched with 29 patients receiving ATG. RESULTS: The median follow-up time was 359 days. Complete donor chimerism was achieved in all patients by STR DNA detection on days +30, +60. The median time to neutrophils ≥0.5×10
